Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
暂无分享,去创建一个
[1] D. Roder,et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. , 2007, Sexual health.
[2] Erik J. Dasbach,et al. Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.
[3] S. Franceschi,et al. Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide , 2006, International journal of cancer.
[4] G. Krogh,et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.
[5] M. Schiffman,et al. Chapter 5: Updating the natural history of HPV and anogenital cancer. , 2006, Vaccine.
[6] D. Lowy,et al. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. , 2006, Vaccine.
[7] Brigitte Colau,et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.
[8] Elamin H Elbasha,et al. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. , 2006, Epidemiologic reviews.
[9] C. Wheeler,et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.
[10] C. Wheeler,et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.
[11] Helen Trottier,et al. The epidemiology of genital human papillomavirus infection. , 2006, Vaccine.
[12] Helen Trottier,et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. , 2006, American journal of epidemiology.
[13] C. Lowndes. Vaccines for cervical cancer , 2006, Epidemiology and Infection.
[14] C. Wheeler,et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.
[15] S. Franceschi,et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.
[16] S. Wacholder,et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. , 2005, The Journal of infectious diseases.
[17] Cosette M Wheeler,et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.
[18] J. Doorbar. The papillomavirus life cycle. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[19] J. Baseman,et al. The epidemiology of human papillomavirus infections. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[20] G. Tortolero-Luna,et al. Human papillomavirus infection: biology, epidemiology, and prevention , 2005, International Journal of Gynecologic Cancer.
[21] J. Peto,et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort , 2004, British Journal of Cancer.
[22] M. Abrahamowicz,et al. Occurrence of Cervical Infection with Multiple Human Papillomavirus Types is Associated with Age and Cytologic Abnormalities , 2003, Sexually transmitted diseases.
[23] C. Rissel,et al. Sex in Australia: A guide for readers , 2003, Australian and New Zealand journal of public health.
[24] C. Rissel,et al. Sex in Australia: The rationale and methods of the Australian Study of Health and Relationships , 2003, Australian and New Zealand journal of public health.
[25] C. Wheeler,et al. A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.
[26] R. Burk,et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. , 2002, The Journal of infectious diseases.
[27] A. Giuliano,et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. , 2002, The Journal of infectious diseases.
[28] N. Kiviat,et al. Concurrent and sequential acquisition of different genital human papillomavirus types. , 2000, The Journal of infectious diseases.
[29] O. Diekmann,et al. Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation , 2000 .
[30] T. Bjørge,et al. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11 , 1999, International journal of cancer.
[31] L. Koutsky,et al. Epidemiology of genital human papillomavirus infections , 1997 .
[32] A. Ades,et al. Modeling age- and time-specific incidence from seroprevalence:toxoplasmosis. , 1993, American journal of epidemiology.
[33] K. Hillman,et al. Intensive Care Medicine , 1992, Annals of Internal Medicine.
[34] Eileen M. Burd,et al. Human Papillomavirus and Cervical Cancer , 1988, The Lancet.
[35] B T Grenfell,et al. The estimation of age-related rates of infection from case notifications and serological data , 1985, Journal of Hygiene.
[36] David R. Scott,et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. , 2001, The Journal of infectious diseases.
[37] R. Anderson,et al. Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. , 1994, IMA journal of mathematics applied in medicine and biology.
[38] M. Lehtinen,et al. Competing Interests: GPG and RVB , 2022 .